Deutsche Bank AG Increases Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Deutsche Bank AG boosted its stake in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 51.4% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 70,961 shares of the company's stock after acquiring an additional 24,104 shares during the period. Deutsche Bank AG owned 0.07% of Dyne Therapeutics worth $1,672,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of DYN. D. E. Shaw & Co. Inc. grew its stake in Dyne Therapeutics by 83.1% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 133,772 shares of the company's stock valued at $3,152,000 after purchasing an additional 60,732 shares during the last quarter. Crestline Management LP lifted its holdings in Dyne Therapeutics by 57.0% during the fourth quarter. Crestline Management LP now owns 184,818 shares of the company's stock valued at $4,354,000 after purchasing an additional 67,137 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Dyne Therapeutics during the fourth quarter worth approximately $2,805,000. Braidwell LP purchased a new position in Dyne Therapeutics during the fourth quarter worth approximately $16,049,000. Finally, Brevan Howard Capital Management LP purchased a new stake in shares of Dyne Therapeutics in the fourth quarter valued at about $678,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

DYN has been the subject of several recent research reports. Evercore ISI assumed coverage on shares of Dyne Therapeutics in a research note on Thursday. They issued an "outperform" rating and a $46.00 price objective for the company. Chardan Capital restated a "buy" rating and set a $50.00 price target on shares of Dyne Therapeutics in a research note on Friday, May 9th. BMO Capital Markets started coverage on shares of Dyne Therapeutics in a report on Wednesday, March 12th. They issued an "outperform" rating and a $50.00 price target for the company. Scotiabank started coverage on shares of Dyne Therapeutics in a research note on Friday, March 7th. They set a "sector outperform" rating and a $50.00 price objective for the company. Finally, HC Wainwright dropped their price objective on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a research note on Friday, May 9th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $47.15.

Dyne Therapeutics Stock Up 4.1%

Shares of NASDAQ:DYN traded up $0.48 during trading on Thursday, hitting $12.24. 1,579,091 shares of the company were exchanged, compared to its average volume of 1,633,518. The business's 50 day moving average is $10.29 and its 200-day moving average is $16.45. The company has a market capitalization of $1.39 billion, a P/E ratio of -3.44 and a beta of 1.19. Dyne Therapeutics, Inc. has a 1-year low of $6.36 and a 1-year high of $47.45.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.17). As a group, sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 earnings per share for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.